世界の伝染病治療薬市場2020-2025:HIV、インフルエンザ、結核、マラリア、肝炎、HPV

LP Informationが発行した調査報告書(LPI21MA03087)
◆英語タイトル:Global Communicable Diseases Drugs Market Growth 2020-2025
◆商品コード:LPI21MA03087
◆発行会社(リサーチ会社):LP Information
◆発行日:2021年1月(※2024年版があります。お問い合わせください。)
◆ページ数:135
◆レポート形式:英語 / PDF
◆納品方法:Eメール(受注後3営業日)
◆調査対象地域:グローバル、日本、アメリカ、ヨーロッパ、アジア、中国など
◆産業分野:医薬品・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD3,660 ⇒換算¥541,680見積依頼/購入/質問フォーム
Multi User(20名様閲覧用)USD5,490 ⇒換算¥812,520見積依頼/購入/質問フォーム
Corporate User(閲覧人数制限なし)USD7,320 ⇒換算¥1,083,360見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はLP Information社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。LP Information社の概要及び新刊レポートはこちらでご確認いただけます。

「伝染病治療薬の世界市場」は、地域的には米州、アジア、欧州、中東・アフリカ市場をカバーしており、種類別には、HIV、インフルエンザ、結核、マラリア、肝炎、HPVなど、用途別には、病院、診療所、その他などに区分してまとめた調査レポートです。伝染病治療薬のグローバル市場規模、主要地域・主要国別、種類別、用途別の市場予測、主要企業の概要・市場シェア・販売量、市場動向などの情報が含まれています。
・伝染病治療薬の世界市場概要(サマリー)
・伝染病治療薬の企業別販売量・売上
・伝染病治療薬の企業別市場シェア
・伝染病治療薬の世界市場規模 2015年-2020年:種類別(HIV、インフルエンザ、結核、マラリア、肝炎、HPV)
・伝染病治療薬の世界市場規模 2015年-2020年:用途別(病院、診療所、その他)
・伝染病治療薬の米州市場規模(アメリカ、カナダ、メキシコなど)
・伝染病治療薬のアジア市場規模(日本、中国、韓国、インド、東南アジアなど)
・伝染病治療薬の欧州市場規模(ドイツ、フランス、イギリス、イタリア、ロシアなど)
・伝染病治療薬の中東・アフリカ市場(エジプト、南アフリカ、トルコ、GCC諸国など)
・伝染病治療薬市場の成長要因・課題・動向
・伝染病治療薬の世界市場予測 2021年-2025年
・伝染病治療薬の米州市場予測(アメリカ、カナダ、メキシコなど)
・伝染病治療薬のアジア市場予測(日本、中国、韓国、インド、東南アジアなど)
・伝染病治療薬の欧州市場予測(ドイツ、フランス、イギリス、イタリア、ロシアなど)
・伝染病治療薬の中東・アフリカ市場予測(エジプト、南アフリカ、トルコ、GCC諸国など)
・伝染病治療薬の世界市場予測:種類別(HIV、インフルエンザ、結核、マラリア、肝炎、HPV)
・伝染病治療薬の世界市場予測:用途別(病院、診療所、その他)
・主要企業分析
【レポートの概要】

According to this study, over the next five years the Communicable Diseases Drugs market will register a xx%% CAGR in terms of revenue, the global market size will reach $ xx million by 2025, from $ xx million in 2019. In particular, this report presents the global market share (sales and revenue) of key companies in Communicable Diseases Drugs business, shared in Chapter 3.

This report presents a comprehensive overview, market shares, and growth opportunities of Communicable Diseases Drugs market by product type, application, key manufacturers and key regions and countries.

This study specially analyses the impact of Covid-19 outbreak on the Communicable Diseases Drugs, covering the supply chain analysis, impact assessment to the Communicable Diseases Drugs market size growth rate in several scenarios, and the measures to be undertaken by Communicable Diseases Drugs companies in response to the COVID-19 epidemic.

Segmentation by type: breakdown data from 2015 to 2020, in Section 2.3; and forecast to 2025 in section 11.7.
HIV
Influenza
TB
Malaria
Hepatitis
HPV

Segmentation by application: breakdown data from 2015 to 2020, in Section 2.4; and forecast to 2024 in section 11.8.
Hospital
Clinic
Other

This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The report also presents the market competition landscape and a corresponding detailed analysis of the major vendor/manufacturers in the market. The key manufacturers covered in this report: Breakdown data in in Chapter 3.
Novartis
Gilead
Janssen Pharmaceutical
Roche
GSK
Boehringer Ingelheim
BioCryst Pharmaceuticals
Merck

In addition, this report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key manufacturers and the market as a whole. It also analyzes key emerging trends and their impact on present and future development.

Research objectives
To study and analyze the global Communicable Diseases Drugs consumption (value & volume) by key regions/countries, type and application, history data from 2015 to 2019, and forecast to 2025.
To understand the structure of Communicable Diseases Drugs market by identifying its various subsegments.
Focuses on the key global Communicable Diseases Drugs manufacturers, to define, describe and analyze the sales volume, value, market share, market competition landscape, SWOT analysis and development plans in next few years.
To analyze the Communicable Diseases Drugs with respect to individual growth trends, future prospects, and their contribution to the total market.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
To project the consumption of Communicable Diseases Drugs submarkets, with respect to key regions (along with their respective key countries).
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
To strategically profile the key players and comprehensively analyze their growth strategies.

【レポートの目次】

1 Scope of the Report
1.1 Market Introduction
1.2 Research Objectives
1.3 Years Considered
1.4 Market Research Methodology
1.5 Data Source
1.6 Economic Indicators
1.7 Currency Considered

2 Executive Summary
2.1 World Market Overview
2.1.1 Global Communicable Diseases Drugs Consumption 2015-2025
2.1.2 Communicable Diseases Drugs Consumption CAGR by Region
2.2 Communicable Diseases Drugs Segment by Type
2.2.1 HIV
2.2.2 Influenza
2.2.3 TB
2.2.4 Malaria
2.2.5 Hepatitis
2.2.6 HPV
2.3 Communicable Diseases Drugs Consumption by Type
2.3.1 Global Communicable Diseases Drugs Consumption Market Share by Type (2015-2020)
2.3.2 Global Communicable Diseases Drugs Revenue and Market Share by Type (2015-2020)
2.3.3 Global Communicable Diseases Drugs Sale Price by Type (2015-2020)
2.4 Communicable Diseases Drugs Segment by Application
2.4.1 Hospital
2.4.2 Clinic
2.4.3 Other
2.5 Communicable Diseases Drugs Consumption by Application
2.5.1 Global Communicable Diseases Drugs Consumption Market Share by Type (2015-2020)
2.5.2 Global Communicable Diseases Drugs Value and Market Share by Type (2015-2020)
2.5.3 Global Communicable Diseases Drugs Sale Price by Type (2015-2020)

3 Global Communicable Diseases Drugs by Company
3.1 Global Communicable Diseases Drugs Sales Market Share by Company
3.1.1 Global Communicable Diseases Drugs Sales by Company (2018-2020)
3.1.2 Global Communicable Diseases Drugs Sales Market Share by Company (2018-2020)
3.2 Global Communicable Diseases Drugs Revenue Market Share by Company
3.2.1 Global Communicable Diseases Drugs Revenue by Company (2018-2020)
3.2.2 Global Communicable Diseases Drugs Revenue Market Share by Company (2018-2020)
3.3 Global Communicable Diseases Drugs Sale Price by Company
3.4 Global Communicable Diseases Drugs Manufacturing Base Distribution, Sales Area, Type by Company
3.4.1 Global Communicable Diseases Drugs Manufacturing Base Distribution and Sales Area by Company
3.4.2 Players Communicable Diseases Drugs Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) (2018-2020)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion

4 Communicable Diseases Drugs by Regions
4.1 Communicable Diseases Drugs by Regions
4.2 Americas Communicable Diseases Drugs Consumption Growth
4.3 APAC Communicable Diseases Drugs Consumption Growth
4.4 Europe Communicable Diseases Drugs Consumption Growth
4.5 Middle East & Africa Communicable Diseases Drugs Consumption Growth

5 Americas
5.1 Americas Communicable Diseases Drugs Consumption by Countries
5.1.1 Americas Communicable Diseases Drugs Consumption by Countries (2015-2020)
5.1.2 Americas Communicable Diseases Drugs Value by Countries (2015-2020)
5.2 Americas Communicable Diseases Drugs Consumption by Type
5.3 Americas Communicable Diseases Drugs Consumption by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
5.8 Key Economic Indicators of Few Americas Countries

6 APAC
6.1 APAC Communicable Diseases Drugs Consumption by Regions
6.1.1 APAC Communicable Diseases Drugs Consumption by Regions (2015-2020)
6.1.2 APAC Communicable Diseases Drugs Value by Regions (2015-2020)
6.2 APAC Communicable Diseases Drugs Consumption by Type
6.3 APAC Communicable Diseases Drugs Consumption by Application
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 Key Economic Indicators of Few APAC Regions

7 Europe
7.1 Europe Communicable Diseases Drugs by Countries
7.1.1 Europe Communicable Diseases Drugs Consumption by Countries (2015-2020)
7.1.2 Europe Communicable Diseases Drugs Value by Countries (2015-2020)
7.2 Europe Communicable Diseases Drugs Consumption by Type
7.3 Europe Communicable Diseases Drugs Consumption by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
7.9 Key Economic Indicators of Few Europe Countries

8 Middle East & Africa
8.1 Middle East & Africa Communicable Diseases Drugs by Countries
8.1.1 Middle East & Africa Communicable Diseases Drugs Consumption by Countries (2015-2020)
8.1.2 Middle East & Africa Communicable Diseases Drugs Value by Countries (2015-2020)
8.2 Middle East & Africa Communicable Diseases Drugs Consumption by Type
8.3 Middle East & Africa Communicable Diseases Drugs Consumption by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries

9 Market Drivers, Challenges and Trends
9.1 Market Drivers and Impact
9.1.1 Growing Demand from Key Regions
9.1.2 Growing Demand from Key Applications and Potential Industries
9.2 Market Challenges and Impact
9.3 Market Trends

10 Marketing, Distributors and Customer
10.1 Sales Channel
10.1.1 Direct Channels
10.1.2 Indirect Channels
10.2 Communicable Diseases Drugs Distributors
10.3 Communicable Diseases Drugs Customer

11 Global Communicable Diseases Drugs Market Forecast
11.1 Global Communicable Diseases Drugs Consumption Forecast (2021-2025)
11.2 Global Communicable Diseases Drugs Forecast by Regions
11.2.1 Global Communicable Diseases Drugs Forecast by Regions (2021-2025)
11.2.2 Global Communicable Diseases Drugs Value Forecast by Regions (2021-2025)
11.2.3 Americas Consumption Forecast
11.2.4 APAC Consumption Forecast
11.2.5 Europe Consumption Forecast
11.2.6 Middle East & Africa Consumption Forecast
11.3 Americas Forecast by Countries
11.3.1 United States Market Forecast
11.3.2 Canada Market Forecast
11.3.3 Mexico Market Forecast
11.3.4 Brazil Market Forecast
11.4 APAC Forecast byRegions
11.4.1 China Market Forecast
11.4.2 Japan Market Forecast
11.4.3 Korea Market Forecast
11.4.4 Southeast Asia Market Forecast
11.4.5 India Market Forecast
11.4.6 Australia Market Forecast
11.5 Europe Forecast by Countries
11.5.1 Germany Market Forecast
11.5.2 France Market Forecast
11.5.3 UK Market Forecast
11.5.4 Italy Market Forecast
11.5.5 Russia Market Forecast
11.6 Middle East & Africa Forecast by Countries
11.6.1 Egypt Market Forecast
11.6.2 South Africa Market Forecast
11.6.3 Israel Market Forecast
11.6.4 Turkey Market Forecast
11.6.5 GCC Countries Market Forecast
11.7 Global Communicable Diseases Drugs Forecast by Type
11.8 Global Communicable Diseases Drugs Forecast by Application

12 Key Players Analysis
12.1 Novartis
12.1.1 Company Information
12.1.2 Communicable Diseases Drugs Product Offered
12.1.3 Novartis Communicable Diseases Drugs Sales, Revenue, Price and Gross Margin (2018-2020)
12.1.4 Main Business Overview
12.1.5 Novartis Latest Developments
12.2 Gilead
12.2.1 Company Information
12.2.2 Communicable Diseases Drugs Product Offered
12.2.3 Gilead Communicable Diseases Drugs Sales, Revenue, Price and Gross Margin (2018-2020)
12.2.4 Main Business Overview
12.2.5 Gilead Latest Developments
12.3 Janssen Pharmaceutical
12.3.1 Company Information
12.3.2 Communicable Diseases Drugs Product Offered
12.3.3 Janssen Pharmaceutical Communicable Diseases Drugs Sales, Revenue, Price and Gross Margin (2018-2020)
12.3.4 Main Business Overview
12.3.5 Janssen Pharmaceutical Latest Developments
12.4 Roche
12.4.1 Company Information
12.4.2 Communicable Diseases Drugs Product Offered
12.4.3 Roche Communicable Diseases Drugs Sales, Revenue, Price and Gross Margin (2018-2020)
12.4.4 Main Business Overview
12.4.5 Roche Latest Developments
12.5 GSK
12.5.1 Company Information
12.5.2 Communicable Diseases Drugs Product Offered
12.5.3 GSK Communicable Diseases Drugs Sales, Revenue, Price and Gross Margin (2018-2020)
12.5.4 Main Business Overview
12.5.5 GSK Latest Developments
12.6 Boehringer Ingelheim
12.6.1 Company Information
12.6.2 Communicable Diseases Drugs Product Offered
12.6.3 Boehringer Ingelheim Communicable Diseases Drugs Sales, Revenue, Price and Gross Margin (2018-2020)
12.6.4 Main Business Overview
12.6.5 Boehringer Ingelheim Latest Developments
12.7 BioCryst Pharmaceuticals
12.7.1 Company Information
12.7.2 Communicable Diseases Drugs Product Offered
12.7.3 BioCryst Pharmaceuticals Communicable Diseases Drugs Sales, Revenue, Price and Gross Margin (2018-2020)
12.7.4 Main Business Overview
12.7.5 BioCryst Pharmaceuticals Latest Developments
12.8 Merck
12.8.1 Company Information
12.8.2 Communicable Diseases Drugs Product Offered
12.8.3 Merck Communicable Diseases Drugs Sales, Revenue, Price and Gross Margin (2018-2020)
12.8.4 Main Business Overview
12.8.5 Merck Latest Developments

13 Research Findings and Conclusion



【免責事項】
https://www.globalresearch.jp/disclaimer

★リサーチレポート[ 世界の伝染病治療薬市場2020-2025:HIV、インフルエンザ、結核、マラリア、肝炎、HPV(Global Communicable Diseases Drugs Market Growth 2020-2025)]についてメールでお問い合わせはこちらでお願いします。